Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights
Rhea-AI Summary
Nuvectis Pharma (NASDAQ: NVCT) reported Q1 2026 results and clinical updates on May 5, 2026. Cash and cash equivalents were $25.1 million as of March 31, 2026, down from $31.6 million at year-end. Net loss was $6.1 million for Q1 2026. The NXP900 Phase 1b program continues to enroll in the US, with preclinical data presented at AACR showing synergy with sotorasib in NSCLC models. Management expects a preliminary Phase 1b data readout in summer 2026 and cited continued financial discipline while advancing clinical milestones.
Positive
- NXP900 Phase 1b continues enrolling patients in US sites
- AACR preclinical data showed synergy with sotorasib in NSCLC models
- Management expects preliminary Phase 1b data in summer 2026
- Cash balance of $25.1M provides near-term operational runway
Negative
- Cash decreased from $31.6M to $25.1M since Dec 31, 2025
- Net loss widened to $6.1M, up $0.8M year‑over‑year
- R&D expenses rose to $4.1M, driven by higher manufacturing costs
News Market Reaction – NVCT
In the May 5 session, NVCT gained 9.22%, reflecting a notable positive market reaction. Argus tracked a peak move of +2.6% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. Trading volume was very high at 3.6x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 11 | Annual results | Positive | +0.5% | 2025 results, stronger cash balance and NXP900 development funding outlook. |
| Nov 04 | Q3 2025 earnings | Positive | -7.5% | Q3 2025 results with cash runway into 3Q-2027 and higher R&D spend. |
| Nov 04 | Q3 2025 earnings | Positive | -7.5% | Third-quarter 2025 update on NXP900 progress and increased net loss. |
| Aug 05 | Q2 2025 earnings | Positive | -5.3% | Q2 2025 results with Phase 1a completion and higher operating expenses. |
| May 06 | Q1 2025 earnings | Positive | -4.4% | Q1 2025 results, financing extension of runway and NXP900 preparation. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historically, NVCT’s earnings-related releases have skewed to negative next-day moves, with an average move of about -4.87%, though one recent annual report saw a small gain.
Recent NVCT earnings updates have combined financial runway disclosures with NXP900 clinical progress. Prior reports highlighted completion of Phase 1a, initiation of Phase 1b, and cash expected to fund milestones into 3Q-2027. Price reactions around these updates have often been negative, notably around Q2 and Q3 2025, despite operational progress. Today’s Q1 2026 results again emphasize NXP900 advancement and cash levels, fitting this established pattern of earnings-focused communication.
Key Terms
Phase 1b medical
monotherapy medical
combination arms medical
non-small cell lung cancer medical
NSCLC medical
RAS inhibitor medical
stock-based compensation financial
clinical trial expenses medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- NXP900 Phase 1b clinical program continues to enroll patients at select sites in the US
- NXP900 preclinical presentations at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting” further support the clinical development strategy
FORT LEE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter of 2026 and provided an update on recent business progress.
Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "2026 is off to a good start for Nuvectis as we advance the NXP900 Phase 1b clinical program which continues to enroll patients at top sites in the US in both the monotherapy and combination arms of the program." Mr. Bentsur added, "At this year’s AACR conference held last month, we provided preclinical data supporting the use of NXP900 in combination with sotorasib, a RAS inhibitor, in non-small cell lung cancer (NSCLC). The combination demonstrated clear synergy both in sotorasib-sensitive and sotorasib-resistant NSCLC models."
Mr. Bentsur concluded, "We are excited for what’s ahead in 2026 and expect a preliminary data readout from the NXP900 Phase 1b study in the summer. We continue to operate with financial discipline and remain focused on achieving key clinical development milestones in our NXP900 program in 2026 and beyond.”
First Quarter 2026 Financial Results
Cash and cash equivalents were
The Company's net loss was
Research and development expenses were
General and administrative expenses were
Finance income was
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing NXP900, a clinical-stage drug candidate. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. Its unique mechanism of action enables inhibition of both the catalytic and scaffolding functions of the SRC kinase, providing comprehensive shutdown of the signaling pathway. NXP900 has completed a Phase 1a dose escalation study, a drug-drug interaction study in healthy volunteers and the Phase 1b program is ongoing.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate", "believe", "contemplate", "could", "estimate", "expect", "intend", "seek", "may", "might", "plan", "potential", "predict", "project", "target", "aim", "should", "will", "would", or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward looking statements are based on Nuvectis Pharma, Inc.'s current expectations and interpretations of data and information available, including preclinical and clinical safety, pharmacokinetics, pharmacodynamics, and efficacy data generated to date for NXP900 and the timing and safety and efficacy data expectations for the monotherapy and combination components of the NXP900 Phase 1b program and estimates and projections regarding our financial condition. The outcomes of the events described in these forward-looking statements are subject to inherent uncertainties, risks, assumptions, market and other conditions, and other factors that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties may also be subject to market and other conditions and described more fully in the section titled "Risk Factors" in our 2025 Form 10-K and our other public filings with the U.S. Securities and Exchange Commission ("SEC"). However, these risks are not exhaustive and new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward looking statements contained in this press release or other filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Company Contact:
Ron Bentsur
Chairman, Chief Executive Officer and President
rbentsur@nuvectis.com
Media Relations Contact:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
| NUVECTIS PHARMA, INC. BALANCE SHEET (USD in thousands, except per share and share amounts) | ||||||||
| March 31, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Assets | ||||||||
| CURRENT ASSETS | ||||||||
| Cash and cash equivalents | $ | 25,130 | $ | 31,634 | ||||
| Other current assets | 268 | 75 | ||||||
| TOTAL CURRENT ASSETS | 25,398 | 31,709 | ||||||
| TOTAL ASSETS | $ | 25,398 | $ | 31,709 | ||||
| Liabilities and Shareholders’ Equity | ||||||||
| CURRENT LIABILITIES | ||||||||
| Accounts payable | $ | 4,695 | $ | 6,274 | ||||
| Accrued liabilities | 36 | 115 | ||||||
| Employee compensation and benefits | 6,447 | 6,907 | ||||||
| TOTAL CURRENT LIABILITIES | 11,178 | 13,296 | ||||||
| TOTAL LIABILITIES | 11,178 | 13,296 | ||||||
| COMMITMENTS AND CONTINGENCIES | ||||||||
| SHAREHOLDERS’ EQUITY | ||||||||
| Common Shares, | * | * | ||||||
| Additional paid in capital | 119,957 | 118,100 | ||||||
| Accumulated deficit | (105,737 | ) | (99,687 | ) | ||||
| TOTAL SHAREHOLDERS’ EQUITY | 14,220 | 18,413 | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 25,398 | $ | 31,709 | ||||
* Represents an amount lower than
| NUVECTIS PHARMA, INC. STATEMENT OF OPERATIONS (USD in thousands, except per share and share amounts) | ||||||||
| Three Months Ended March 31 | ||||||||
| 2026 | 2025 | |||||||
| OPERATING EXPENSES | ||||||||
| Research and development | $ | 4,106 | $ | 3,680 | ||||
| General and administrative | 2,154 | 1,888 | ||||||
| OPERATING LOSS | (6,260 | ) | (5,568 | ) | ||||
| Finance income | 210 | 236 | ||||||
| NET LOSS | $ | (6,050 | ) | $ | (5,332 | ) | ||
| TOTAL NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | $ | (6,050 | ) | $ | (5,332 | ) | ||
| BASIC AND DILUTED NET LOSS PER COMMON SHARE OUTSTANDING | $ | (0.26 | ) | $ | (0.27 | ) | ||
| Basic and diluted weighted average number of common shares outstanding | 23,414,475 | 19,937,507 | ||||||
